Why are rheumatologists treating lupus nephritis?

Nature Clinical Practice Nephrology

Volumn 3, Issue 6, 2007, Pages 296-297

  Bargman, Joanne M ^a,b,c  

^a Peritoneal Dialysis Program   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; UREA;

ANTIBIOTIC PROPHYLAXIS; CHRONIC KIDNEY DISEASE; CONSENSUS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL LITERATURE; NEPHROLOGIST; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PUBLICATION; RENAL REPLACEMENT THERAPY; RESPONSIBILITY; RHEUMATOLOGY; SEPSIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; URINALYSIS; URINE VOLUME;

CLINICAL COMPETENCE; HUMANS; LUPUS NEPHRITIS; NEPHROLOGY; RHEUMATOLOGY;

EID: 34249713718     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0489     Document Type: Short Survey

References (1)

1. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (2006) The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54: 421-432